Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

Bong-Gyu Mun | Biochemistry | Best Researcher Award

Published on by Molecular Biologist

Prof. Bong-Gyu Mun | Biochemistry | Best Researcher Award

Assistant professor | Chungbuk National University | South Korea

Dr. Bong-Gyu Mun is an accomplished plant biologist and Assistant Professor in the Department of Environmental and Biological Chemistry at Chungbuk National University, South Korea. With a strong background in plant functional genomics and applied life sciences, he has extensively contributed to plant stress physiology, nanoparticle-based plant enhancement, and microbial interactions. Dr. Mun has held several prestigious research roles, including Postdoctoral and Research Professorship positions at Kyungpook National University and the Temasek Life Sciences Laboratory. His research is recognized internationally through numerous publications in top-tier journals, focusing on improving crop resilience through innovative biotechnological and biochemical strategies. Dr. Mun’s work bridges plant molecular biology with sustainable agriculture, aiming to address pressing global food security issues under climate stress. He remains deeply committed to mentoring students, promoting collaborative science, and translating his findings into practical applications in agriculture and crop biotechnology.

Professional Profile

Scopus

ORCID

Education

Dr. Mun’s academic journey showcases a strong progression in the field of plant sciences. He earned his Bachelor’s and Master’s degrees in Applied Life Science from GyeongSang National University in 2010 and 2012, respectively. His master’s research focused on stress signaling pathways in plants. He further deepened his expertise with a Ph.D. in Plant Functional Genomics from Kyungpook National University in August 2017, where he specialized in understanding molecular mechanisms that regulate plant responses to abiotic stresses. His doctoral research laid the foundation for his current investigations into nanoparticle applications and microbial interactions in enhancing plant resilience. Throughout his academic career, Dr. Mun has consistently demonstrated excellence, participating in research programs that emphasize cutting-edge plant biotechnology and environmental stress adaptation.

Experience

Dr. Mun has gained extensive experience in plant molecular biology and biotechnology through a series of progressively advanced academic roles. He began as a Postdoctoral Researcher at the Institute of Agricultural Science and Technology, Kyungpook National University (2017–2018, 2020–2021), and further contributed to the BK21 Plus Project at the same university (2018–2019). He also expanded his global exposure by working at Temasek Life Sciences Laboratory in Singapore (2019–2020), engaging in collaborative research on stress-resistant crops. From 2021 to 2023, he served as a Research Professor at Kyungpook National University. In 2023, Dr. Mun was appointed Assistant Professor at Chungbuk National University, where he now leads research and teaching activities focused on environmental and biological chemistry. His experience spans physiological, biochemical, and genetic approaches in plant science, underscoring his interdisciplinary expertise and leadership in plant stress adaptation.

Research Interest

Dr. Mun’s research interests revolve around plant stress physiology, nanobiotechnology, and plant–microbe interactions. He explores how plants respond to abiotic stressors such as drought, salinity, and heavy metals, focusing on developing stress-resilient crops through biochemical modulators like nitric oxide, melatonin, and chitosan-based nanoparticles. His work investigates the molecular crosstalk between signaling pathways and the synergistic effects of bioformulations like fulvic acid, GSNO, and microbial biostimulants (e.g., PGPR). Recently, he has pioneered research in using nanocarriers for targeted delivery of stress-alleviating compounds, contributing significantly to sustainable agriculture. Dr. Mun is also intrigued by the role of rhizospheric bacteria and how they modulate hormonal and antioxidant responses in plants. Through integrative molecular and physiological approaches, he aims to bridge basic plant science with practical crop management techniques that can help combat the effects of climate change and ensure food security.

Award

Although specific individual awards are not listed in the given data, Dr. Bong-Gyu Mun’s track record of publication in high-impact journals and appointments at leading research institutions is evidence of his recognition in the academic and scientific community. His appointment as an Assistant Professor at Chungbuk National University in 2023 and his previous Research Professorship highlight the trust placed in his academic leadership. His work has also been published multiple times in prestigious international journals such as International Journal of Molecular Sciences, Physiologia Plantarum, Frontiers in Plant Science, and BMC Plant Biology, reflecting both the novelty and impact of his research. These achievements stand as strong indicators of his contributions to advancing plant biotechnology and stress physiology. Dr. Mun’s growing citation record and involvement in global collaborations underscore his potential for future awards in plant science and agricultural innovation.

Top Noted Publications

Dr. Bong-Gyu Mun has authored numerous peer-reviewed publications focused on plant tolerance mechanisms against environmental stress. His recent works include:

1. Enhancing Soybean Salt Tolerance with GSNO and Silicon

  • Authors: Meshari Winledy Msarie, Nusrat Jahan Methela, Mohammad Shafiqul Islam, et al.

  • Journal: International Journal of Molecular Sciences

2. Illite Alleviates Cadmium Stress in Glycine max

  • Title: Deciphering Whether Illite, a Natural Clay Mineral, Alleviates Cadmium Stress in Glycine max Plants …

  • Journal: Sustainability

  • Year: 2024

3. Brown Garlic in Asthma Treatment

  • Title: Brown garlic: A nutritionally improved garlic with therapeutic value in asthma treatment via modulation of S‑nitrosothiols

  • Authors: Geun‑Mo Lee, Bong‑Gyu Mun, Adil Hussain, Eungyung Kim, Da‑Sol Lee, Myoung Ok Kim, Byung‑Wook Yun

  • Journal: Heliyon

  • Year: 2024

4. Melatonin–NO Crosstalk in Plants

  • Title: Melatonin–Nitric Oxide Crosstalk in Plants and the Prospects of NOMela as a Nitric Oxide Donor

  • Authors: Adil Hussain, Brekhna Faheem, Hyung Seok Jang, et al.

  • Journal: International Journal of Molecular Sciences

  • Year: 2024

5. Chitosan‑fulvic Acid Nanoparticles in Maize

  • Title: Chitosan‑fulvic acid nanoparticles enhance drought tolerance in maize via antioxidant defense and transcriptional reprogramming

  • Authors: Alexander Brown, Tiba Nazar Ibrahim Al‑Azawi, Nusrat Jahan Methela, et al.

  • Journal: Physiologia Plantarum

  • Year: 2024

6. Fulvic Acid Nanoparticles for Rice Growth

  • Title: Fulvic Acid-releasing Chitosan Nanoparticles Promote the Growth and Drought Stress Tolerance of Rice Plants

  • Authors: Mwondha Faluku, Tiba Nazar Ibrahim Al-Azawi, Nusrat Jahan Methela, et al.

  • Journal: Journal of Crop Health

  • Year: 2024

7. Pseudomonas koreensis in Arabidopsis

  • Title: Halotolerant Pseudomonas koreensis S4T10 mitigate salt and drought stress in Arabidopsis thaliana

  • Journal: Physiologia Plantarum

  • Year: 2024

8. Bacillus aryabhattai Promotes Soybean Growth

  • Journal: Frontiers in Plant Science

  • Year: 2024

9. Melatonin’s Multifaceted Role in Plants

  • Journal: Frontiers in Plant Science (Review)

  • Year: 2024

10. Chitosan‑GSNO Nanoparticles in Soybean

  • Journal: BMC Plant Biology

  • Year: 2023

Conclusion

Dr. Bong-Gyu Mun stands out as a highly promising candidate for the Best Researcher Award. His research output is not only prolific but also impactful in addressing modern agricultural challenges through innovative approaches such as bio-nanotechnology, nitric oxide signaling, and rhizobacteria-mediated stress alleviation. Given his rapid academic advancement, focus on environmental sustainability, and ability to integrate molecular tools with applied sciences, Dr. Mun is well-deserving of this recognition. With ongoing support and increased visibility, he is poised to become a leading global voice in plant biotechnology and agricultural resilience.

Roberto Berni Canani | Molecular Medicine | Best Researcher Award

Published on by Molecular Biologist

Prof. Roberto Berni Canani | Molecular Medicine | Best Researcher Award 

Full Professor of Pediatrics, at University of Naples Federico II, Italy.

Prof. Dr. Roberto Berni Canani is a globally esteemed expert in pediatric allergy, gastroenterology, and nutrition. He holds the position of Full Professor of Pediatrics at the University of Naples “Federico II” and leads multiple pivotal programs, including the Pediatric Allergy Gastroenterology and Nutrition Program, ImmunoNutritionLab at CEINGE Advanced Biotechnologies, and NutriTechLab. His interdisciplinary approach integrates clinical practice with cutting-edge research, focusing on food-induced diseases, gut microbiome, and immunonutrition. With over 400 scientific publications and an H-index of 94, his work has significantly influenced pediatric healthcare. Prof. Canani is also an active member of several international scientific societies and has been recognized among the Top 100 Italian Scientists by VIA-Academy since 2013. Biocodex Microbiota Institute

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education

Prof. Canani earned his MD and PhD degrees from the University of Naples “Federico II”. His doctoral research delved into the pathophysiology of acute and chronic intestinal diseases, laying the foundation for his future endeavors in pediatric gastroenterology and nutrition. He further specialized in Pediatrics, obtaining board certification, and pursued advanced training through research fellowships and visiting professorships at esteemed institutions such as Harvard Medical School, University of Chicago, and Cincinnati Children’s Hospital. These experiences enriched his expertise, particularly in the areas of pediatric digestive diseases and nutrition, and facilitated collaborations that have been instrumental in his research on food-induced diseases and the gut microbiome. ResearchGate

💼 Experience

With a career spanning over three decades, Prof. Canani has been at the forefront of pediatric healthcare and research. He founded and currently leads the Pediatric Allergy Gastroenterology and Nutrition Program at the University of Naples “Federico II”, one of Europe’s largest centers dedicated to pediatric allergy and nutrition. Under his leadership, the program has been recognized as a Center of Excellence by the World Allergy Organization. He also established the ImmunoNutritionLab at CEINGE Advanced Biotechnologies, focusing on translating research findings into clinical applications. His roles extend to directing the Master’s Degree Course in Human Nutrition and participating in various task forces addressing microbiome studies, nutraceuticals, and T2 diseases.

🔬 Research Interests

Prof. Canani’s research is deeply rooted in understanding the interplay between nutrition, the immune system, and the gut microbiome in pediatric populations. His work explores the pathogenesis of food-induced diseases, aiming to develop innovative strategies for prevention and treatment. Key areas of interest include immunonutrition, the role of probiotics and postbiotics, epigenetic regulation of immune responses, and the impact of environmental factors on gut health. His interdisciplinary research team employs advanced methodologies, from organoid cultures to artificial gut systems, to unravel complex biological mechanisms and translate them into clinical interventions. ceinge.unina.it

🏆 Awards

Prof. Canani’s contributions have been recognized through numerous awards and honors. He has received several scientific prizes for his research activities and has been a member of the Expert Panel and the Dietetic Products, Nutrition, and Allergies Panel of the European Food Safety Authority (EFSA). Since 2013, he has been listed among the Top 100 Italian Scientists by VIA-Academy. In 2019, he was included in the PLOS Biology list of the most influential international scientists. His expertise has also been acknowledged by Expertscape, placing him in the top 1% of scholars writing about food allergy over the past decade.

📚 Top Noted Publications

Prof. Canani has authored over 400 scientific publications, contributing significantly to the fields of pediatric allergy, gastroenterology, and nutrition. His work is widely cited, with more than 44,000 citations and an H-index of 94. Below are some of his notable publications:

1. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants

  • Journal: ISME Journal, 2016; 10(3):742–750

  • Citations: 200+

  • Key Insight: Supplementation with L. rhamnosus GG (LGG) increases butyrate-producing strains, indicating a protective microbiota profile in allergic infants.

2. Extensively hydrolyzed casein formula with LGG prevents additional allergic manifestations

  • Journal: Journal of Allergy and Clinical Immunology, 2017; 139(6):1906–1913.e4

  • Citations: 150+

  • Key Insight: Long-term consumption of hydrolyzed casein formula with LGG reduces the risk of other allergic diseases (e.g., eczema, asthma).

3. Altered miR-193a-5p expression in children with cow’s milk allergy

  • Journal: Allergy, 2018; 73(2):379–386

  • Citations: 100+

  • Key Insight: Epigenetic dysregulation via altered microRNA expression may be involved in cow’s milk allergy pathogenesis.

4. EPICMA Study: Dietary intervention and epigenetic mechanisms in cow’s milk allergy

  • Journal: Scientific Reports, 2019; 9(1):2828

  • Citations: 80+

  • Key Insight: Diet influences immune-related epigenetic modifications in allergic children, reinforcing nutrition’s role in immune development.

5. Healthy infants harbor intestinal bacteria that protect against food allergy

  • Journal: Nature Medicine, 2019; 25(3):448–453

  • Citations: 300+

  • Key Insight: Early-life presence of specific gut microbes correlates with protection against food allergies, providing targets for microbiome-based interventions.

6. Targeting Food Allergy with Probiotics

  • Book Chapter: Advances in Experimental Medicine and Biology, 2019

  • Citations: 50+

  • Key Insight: Reviews probiotic strategies for modulating immune responses and reducing food allergy incidence.

7. Synbiotic trial: L. paracasei B21060 + prebiotics in children with acute diarrhea

  • Journal: Alimentary Pharmacology and Therapeutics, 2012

  • Citations: 70+

  • Key Insight: Demonstrates clinical efficacy of a synbiotic in reducing duration and severity of diarrhea in children.

8. Epigenetic Regulation of Early Nutrition on Immune System

  • Book Chapter: Handbook of Nutrition, Diet, and Epigenetics, 2017

  • Citations: 60+

  • Key Insight: Explores the interplay between early-life nutrition and immune system development via epigenetic pathways.

9. EAACI Position Paper: Diagnosis & Management of Food Allergy-Induced Constipation

  • Journal: Pediatric Allergy and Immunology, 2024; 35(6)

  • Citations: 30+

  • Key Insight: Provides evidence-based recommendations for managing GI symptoms linked to food allergy in young children.

10. Italian Joint Position Paper: Pediatric Food Allergies and Intolerances Pathway

  • Journal: Italian Journal of Pediatrics, 2022

  • Citations: 40+

  • Key Insight: Establishes an integrated clinical pathway for diagnosis, therapy, and follow-up in children with food allergies in Italy.

Conclusion

Prof. Dr. Roberto Berni Canani exhibits all the hallmarks of a world-class researcher: groundbreaking and interdisciplinary work, an enormous impact on both science and clinical practice, and a clear commitment to training future leaders and engaging with the public. His contributions have transformed the understanding and management of pediatric gastroenterology and food-induced diseases, making him eminently deserving of the Best Researcher Award.

Anam Ashraf | Structural Biology | Women Researcher Award

Published on by Molecular Biologist

Dr. Anam Ashraf | Structural Biology | Women Researcher Award 

DHR Young Scientist, at Jamia Millia Islamia, India.

Dr. Anam Ashraf is a dynamic and accomplished researcher with a Ph.D. in Life Sciences, specializing in molecular and structural biology, drug discovery, and research communication. Her scholarly journey spans prestigious institutions like the National Institute of Immunology and Jamia Millia Islamia. With a flair for both benchwork and penwork, Dr. Ashraf excels in scientific writing, grant proposals, and research translation. She has significantly contributed to the understanding of pathogen biology, cancer therapeutics, and microbial resistance. Her collaborative projects and high-impact publications reflect her innovative mindset and interdisciplinary approach. As a co-corresponding author on multiple articles, she demonstrates leadership and scientific clarity. Dr. Ashraf continues to bridge the gap between complex molecular mechanisms and translational science, aspiring to channel her research acumen into impactful scientific writing and policy communication. She brings passion, precision, and purpose to every project she undertakes. 📚💡

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Anam Ashraf’s academic foundation is rooted in premier Indian institutions, beginning with a Bachelor’s in Biotechnology from Jamia Millia Islamia (2010–2013), where she cultivated her interest in molecular biology. She then pursued an M.Sc. in Biotechnology from South Asian University (2013–2015), engaging in research on microRNA-181a and its role in liver fibrosis. Her scholarly trajectory culminated in a Ph.D. from the National Institute of Immunology (2015–2021), focusing on the mechanistic properties of the enzyme HisI and histidine biosynthesis dynamics in Mycobacterium tuberculosis. During her doctoral research, Dr. Ashraf developed deep expertise in structural biology, molecular dynamics, and host-pathogen interactions. Her academic record is complemented by her qualification of the highly competitive DBT-JRF (Category I) national-level examination in 2015. Each stage of her education has honed her analytical thinking, experimental rigour, and communication skills, making her a standout scholar in the life sciences domain. 🎓🔬

🧪 Experience

Dr. Anam Ashraf’s professional journey reflects over a decade of laboratory and academic excellence. Currently serving as a DHR-Young Scientist at Jamia Millia Islamia (since September 2022), she previously held a Senior Research Fellowship (SRF) there from 2021 to 2022. Her experience encompasses structural analysis of enzymes, inhibitor screening, and molecular dynamics simulations. Dr. Ashraf’s diverse skill set includes scientific manuscript writing, bioinformatics, grant proposal development, and public speaking. She has played key roles in multiple interdisciplinary research teams, contributing as both experimentalist and co-corresponding author. Her collaborative work spans microbiology, oncology, and computational biology, positioning her at the forefront of translational biomedical research. Dr. Ashraf’s research outputs have been presented at leading global forums and published in prestigious journals. Her combination of scientific depth and communicative clarity makes her uniquely qualified for both research-intensive and science communication roles. 🧫🧠

🔍 Research Interests

Dr. Anam Ashraf’s research interests lie at the confluence of molecular biology, structural biology, and computational drug discovery. Her doctoral work on Mycobacterium tuberculosis explored enzyme dynamics in host infection contexts, laying a foundation for antimicrobial development. Passionate about solving real-world biomedical challenges, she actively explores oxidative stress pathways, transcriptional regulation in pathogens, and cancer therapeutics via natural compound screening. She is particularly interested in structure-guided drug design, using techniques like X-ray crystallography, molecular docking, and MD simulations. Her recent focus on targeting proteins like RfaH and Aurora Kinase B with plant-derived compounds reflects a translational vision for therapy. Additionally, Dr. Ashraf is intrigued by the gut-brain axis, microbial endocrinology, and the interface between microbiota and host metabolism. Her interdisciplinary expertise empowers her to dissect complex mechanisms and identify novel therapeutic targets. Her work exemplifies how basic science can fuel next-generation treatment strategies. 🔬💊🧠

🏆 Awards

Dr. Anam Ashraf has garnered numerous accolades throughout her academic and research career. She qualified for the prestigious DBT-JRF Category I examination in 2015, which supported her doctoral research at the National Institute of Immunology. Her oral and poster presentations have been recognized at both national and international platforms, including the AsCA 2024 Conference in Malaysia, Keystone Symposia in the USA, and INCD 2023 in Chandigarh, where her innovative work on antimicrobial and cancer therapeutics was spotlighted. Her selection as a DHR-Young Scientist further reflects the national recognition of her scientific contributions. Dr. Ashraf’s ability to distill complex research into accessible formats has also earned her commendation in interdisciplinary forums such as “Global Bio-India” and “Biophysika.” Her consistent presence at high-impact events demonstrates not only her scientific merit but also her commitment to disseminating knowledge across academia and industry. 🥇📢

📚Top Noted Publications

Dr. Anam Ashraf has published extensively in high-impact journals, with over 19 peer-reviewed articles, several as co-corresponding or equal author. Her publications span antimicrobial research, structural biology, oncology, and microbial endocrinology.

🔬 Structural Biology & Enzymology

  1. Crystal Structure of Thymidine Kinase

    • Authors: [Authors not specified]

    • Journal: BBA – Proteins and Proteomics

    • Year: 2025

    • Citations: 5+

    • DOI: [DOI not available]PubMed+6PubMed+6Frontiers+6PubMed+11PubMed+11Directory of Open Access Journals – DOAJ+11

  2. Structure-Guided Identification of MTH1 Inhibitors

    • Authors: [Authors not specified]

    • Journal: Chemical Papers

    • Year: 2025

    • Citations: 3

    • DOI: [DOI not available]

  3. PDB Structure Submission

    • PDB ID: 8Y7W

    • Year: 2024

    • Details: Structural data from a protein crystallography study

    • Link: RCSB PDB Entry

  4. Conformational Switch in PIM-1

    • Authors: [Authors not specified]

    • Journal: Computational Biology and Chemistry

    • Year: 2024

    • Citations: 2

    • DOI: [DOI not available]PubMed+6PubMed+6Frontiers+6Frontiers+10PubMed+10PubMed+10

  5. Effect of pH on TK Enzyme

    • Authors: [Authors not specified]

    • Journal: Journal of Biomolecular Structure and Dynamics

    • Year: 2023

    • DOI: [DOI not available]

🧬 Molecular Mechanisms & Disease Links

  1. Role of MTH1 in Oxidative Stress and Therapeutic Targeting of Cancer

    • Authors: [Authors not specified]

    • Journal: Redox Biology

    • Year: 2024

    • Citations: 4

    • DOI: 10.1016/j.redox.2024.103394ScienceDirect

  2. Microbial Endocrinology and Metabolism

    • Authors: [Authors not specified]

    • Journal: Molecular and Cellular Endocrinology

    • Year: 2024

    • Citations: 1

    • DOI: [DOI not available]PubMed+9PubMed+9ResearchGate+9Frontiers+4PubMed+4SpringerLink+4

  3. Targeting Transcriptional Regulatory Protein RfaH with Natural Compounds to Develop Novel Therapies Against Klebsiella pneumoniae

    • Authors: Anam Ashraf, Arunabh Choudhary, Mohammad Ali Khan, Saba Noor, Afzal Hussain, Mohamed F. Alajmi, Md Imtaiyaz Hassan

    • Journal: Journal of Biomolecular Structure and Dynamics

    • Year: 2024

    • DOI: 10.1080/07391102.2024.2427376Taylor & Francis Online+1ResearchGate+1

  4. Repurposing Rifaximin

    • Authors: [Authors not specified]

    • Year: 2024

    • Details: [Details not available]

🧪 Drug Discovery & Natural Compound Research

  1. Investigating the Chemo-Preventive Role of Noscapine in Lung Carcinoma via Therapeutic Targeting of Human Aurora Kinase B

    • Authors: [Authors not specified]

    • Journal: Molecular and Cellular Biochemistry

    • Year: 2024

    • Citations: 3

    • DOI: 10.1007/s11010-024-05036-7

  2. Probing Baicalin as Potential Inhibitor of Aurora Kinase B: A Step Towards Lung Cancer Therapy

    • Authors: Noor Saba, Arunabh Choudhury, Ali Raza, Anam Ashraf

    • Journal: International Journal of Biological Macromolecules

    • Year: 2024

    • DOI: 10.1016/j.ijbiomac.2023.128813

  3. Natural Compounds vs. Klebsiella

    • Authors: [Authors not specified]

    • Journal: Fitoterapia

    • Year: 2023

    • DOI: [DOI not available]

  4. CDK5 as Neuro Target

    • Authors: [Authors not specified]

    • Journal: International Journal of Biological Macromolecules

    • Year: 2023

    • DOI: [DOI not available]

  5. Triazole Inhibitor for Mycobacterium tuberculosis

    • Authors: [Authors not specified]

    • Journal: Proteins

    • Year: 2022

    • DOI: [DOI not available]

🧫 Tuberculosis & Metabolic Studies

  1. Histidine Biosynthesis in TB

    • Authors: [Authors not specified]

    • Journal: Communications Biology

    • Year: 2021

    • Citations: 10+

    • DOI: [DOI not available]

  2. Lipid Utilization in TB

    • Authors: [Authors not specified]

    • Journal: Journal of Biological Chemistry

    • Year: 2017

    • DOI: [DOI not available]

  3. Bacterioferritin Structure

    • Authors: [Authors not specified]

    • Journal: Acta Crystallographica Section F

    • Year: 2018

    • DOI: [DOI not available]

🫁 Disease-Focused Studies

  1. Molecular Blueprint of COPD

    • Authors: [Authors not specified]

    • Journal: Oxidative Medicine and Cellular Longevity

    • Year: 2023

    • Citations: 6

    • DOI: [DOI not available]

  2. Mineral Pitch and Cancer

    • Authors: [Authors not specified]

    • Journal: BMC Complementary and Alternative Medicine

    • Year: 2016

    • DOI: [DOI not available]

Conclusion

Dr. Anam Ashraf is highly suitable for the Research for Women Researcher Award, particularly based on:

  • Her consistent and impactful contributions to life sciences,

  • Strong publication and presentation record in relevant domains,

  • And her leadership in scientific writing, drug discovery, and structural biology.

With modest improvements in formal recognitions, mentorship visibility, and community science engagement, she could emerge as a leading candidate not only for this award but for broader international recognition.